{
  "id": "5c961603ecadf2e73f000022",
  "type": "list",
  "question": "List off label uses for Rituximab.",
  "ideal_answer": "Off label uses for rituximab are for poly- and dermatomyositis, multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus (SLE), lupus nephritis (LN), and other immune diseases.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29797711",
    "http://www.ncbi.nlm.nih.gov/pubmed/28742259",
    "http://www.ncbi.nlm.nih.gov/pubmed/29574922",
    "http://www.ncbi.nlm.nih.gov/pubmed/30185361",
    "http://www.ncbi.nlm.nih.gov/pubmed/18270863",
    "http://www.ncbi.nlm.nih.gov/pubmed/28536935"
  ],
  "snippets": [
    {
      "text": "Analysis of the data of the GRAID-2 registry for poly- and dermatomyositis.RESULTS: In 22\u00a0of the 23\u00a0patients in the GRAID-2 registry, rituximab (RIX) was administered, while 1\u00a0patient was given tocilizumab as off-label therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28536935",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Off-label use of rituximab to treat MS patients in Sweden is high",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29797711",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28742259",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "immune thrombocytopenia who do not adequately respond to first-line therapy, there is no clear consensus on which second-line therapy to initiate and when. This situation leads to suboptimal approaches, including prolonged exposure to treatments that are not intended for long-term use (eg, corticosteroids) and overuse of off-label therapies (eg, rituximab) ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29574922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conventional treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN) is associated with damage accrual, hence increased morbidity rate. Off-label use of rituximab (RTX) has shown significant promise in this patient group; however, data are still controversial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30185361",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Outcomes of rituximab therapy in refractory lupus: A meta-analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30185361",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Rituximab seems to have an interesting benefit-to-risk ratio in Wegener granulomatosis (excepted in granulomatous lesions), HCV-associated symptomatic cryoglobulinemia in patients unresponsive to anti-viral therapy, pemphigus and thrombotic thrombocytopenic purpura.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18270863",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "poly- and dermatomyositis, multiple sclerosis, auto immune disease, immune thrombocytopenia, systemic lupus erythematosus (SLE), lupus nephritis (LN)"
}